Journal of Pharmacological Sciences
Online ISSN : 1347-8648
Print ISSN : 1347-8613
ISSN-L : 1347-8613

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders:
Regulation of Dopaminergic Neural Transmission by Tyrosine Hydroxylase Protein at Nerve Terminals
Chiho Sumi-IchinoseHiroshi IchinoseKazuhisa IkemotoTakahide NomuraKazunao Kondo
著者情報
ジャーナル フリー 早期公開

論文ID: 09R28FM

この記事には本公開記事があります。
詳細
抄録
5R-L-Erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for tyrosine hydroxylase (TH). Recently, a type of dopa-responsive dystonia (DRD) (DYT5, Segawa’s disease) was revealed to be caused by dominant mutations of the gene encoding GTP cyclohydrolase I (GCHI), which is the rate-limiting enzyme of BH4 biosynthesis. In order to probe the role of BH4 in vivo, we established BH4-depleted mice by disrupting the 6-pyruvoyltetrahydropterin synthase (PTS) gene (Pts−/−) and rescued them by introducing human PTS cDNA under the control of the human dopamine β-hydroxylase (DBH) promoter (Pts−/−-DPS). The Pts−/−-DPS mice developed hyperphenylalaninemia. Interestingly, tyrosine hydroxylase protein was dramatically reduced in the dopaminergic nerve terminals of these mice, and they developed abnormal posture and motor disturbance. We propose that the biochemical and pathologic changes of Pts−/−-DPS mice are caused by mechanisms common to human DRD, and understanding these mechanisms could give us insight into other movement disorders.
著者関連情報
© The Japanese Pharmacological Society 2010
feedback
Top